Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.78 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.78 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 4/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620297 | 1.00 | CHRNB2 (0.78) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| SCHEMBL621495 | 1.00 | CHRNB2 (0.78) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| SCHEMBL617913 | 1.00 | CHRNB2 (0.78) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| SCHEMBL621496 | 1.00 | CHRNB2 (0.78) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| SCHEMBL617912 | 1.00 | CHRNB2 (0.78) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| Hydrochloric Acid SCHEMBL3959048 | 0.99 | CHRNB2 (0.76) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| Hydrochloric Acid SCHEMBL3958637 | 0.99 | CHRNB2 (0.76) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| Phosphoric Acid SCHEMBL3957257 | 0.92 | CHRNB2 (0.67) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| Fumaric Acid SCHEMBL3961180 | 0.90 | CHRNB2 (0.65) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA | |
| Maleic Acid SCHEMBL3952127 | 0.90 | CHRNB2 (0.65) | CHRNB2CHRNA4ROCK2MAP4K4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | claimed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | claimed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| WO-2009018367-A2 | NOVEL SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-METHOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-10-09 | — | — | US | claimed |
| WO-2008091592-A1 | INTRANASAL, BUCCAL, AND SUBLINGUAL ADMINISTRATION OF METANICOTINE ANALOGS | TARGACEPT, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | claimed |
| EP-1814853-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-12-28 | — | — | US | claimed |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | DULL GARY M | 2006-06-08 | — | — | US | claimed |
| WO-2006053039-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-7045538-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2006-05-16 | — | — | US | claimed |
| JP-2006511482-A | — | — | 2006-04-06 | — | — | JP | claimed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | claimed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | claimed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-1814852-B1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | CATALYST BIOSCIENCES INC (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9107915-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9040568-B2 | Pharmaceutical compositions for the treatment of pain | ABBVIE INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8778978-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8703802-B2 | Process for the preparation of aryl substituted olefinic amines | TARGACEPT, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703802-B2 | Process for the preparation of aryl substituted olefinic amines | TARGACEPT, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8580826-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130225827-A1 | New Process for the Preparation of Aryl Substituted Olefinic Amines | TARGACEPT, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225827-A1 | New Process for the Preparation of Aryl Substituted Olefinic Amines | TARGACEPT, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8486979-B2 | Analgesics; central nervous system disorders; attentiondeficit disorders;cognition activators; bipolar disorders; Alzheimer's disease; Down's syndrome; brain disorders | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2371818-B1 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MUNOZ JULIO A (US) | 2012-02-16 | — | — | US | disclosed |
| US-8053451-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2371818-A1 | Hydroxybenzoate salts of metanicotine compounds | Targacept, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-7994223-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110190314-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2297140-A1 | NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010138600-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | disclosed |
| US-7786171-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2009018367-A3 | SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-METHOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | TARGACEPT, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100028447-A1 | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs | TARGACEPT, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028447-A1 | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs | TARGACEPT, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028447-A1 | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs | TARGACEPT, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009148452-A1 | NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2119476-A2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-2112923-A1 | INTRANASAL, BUCCAL, AND SUBLINGUAL ADMINISTRATION OF METANICOTINE ANALOGS | Targacept Inc. (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090062321-A1 | Hydroxybenzoate Salts Of Metanicotine Compounds | TARGACEPT, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009018367-A2 | NOVEL SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-METHOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018367-A2 | NOVEL SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-METHOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018367-A2 | NOVEL SALT FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-METHOXYPYRIDIN)YL]-4-PENTEN-2-AMINE | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-7459469-B2 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008091588-A1 | INTRANASAL, BUCCAL, AND SUBLINGUAL ADMINISTRATION OF METANICOTINE ANALOGS | TARGACEPT, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008091592-A1 | INTRANASAL, BUCCAL, AND SUBLINGUAL ADMINISTRATION OF METANICOTINE ANALOGS | TARGACEPT, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1814852-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1814853-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060122237-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. | 2006-06-08 | — | — | US | disclosed |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | DULL GARY M | 2006-06-08 | — | — | US | disclosed |
| WO-2006053082-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006053039-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | DULL GARY MAURICE (US) | 2003-05-08 | — | — | US | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | CHRNB2 8/4885CHRNA4 1/4885ROCK2 3185/4885 |
| US-20130225827-A1 | New Process for the Preparation of Aryl Substituted Olefinic Amines | PNMT, MAOB, AOC2 | CHRNB2 962/4885CHRNA4 476/4885ROCK2 2309/4885 |
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 573/4885CHRNA4 1876/4885ROCK2 3807/4885 |
| US-20110190314-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885ROCK2 2944/4885 |
| US-20060122237-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | NTRK1, CHRNA10, CHRNB2 | CHRNB2 3/4885CHRNA4 21/4885ROCK2 4239/4885 |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885ROCK2 3771/4885 |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885ROCK2 3771/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885ROCK2 3629/4885 |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, HTR3E | CHRNB2 227/4885CHRNA4 145/4885ROCK2 2569/4885 |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 573/4885CHRNA4 1876/4885ROCK2 3807/4885 |
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | CHRNA1, CHRNG, CHRNA4 | CHRNB2 14/4885CHRNA4 3/4885ROCK2 1907/4885 |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885ROCK2 3771/4885 |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | CHRNB2 3741/4885CHRNA4 4109/4885ROCK2 584/4885 |
| US-20100028447-A1 | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs | MTNR1B, MTNR1A, MTX1 | CHRNB2 600/4885CHRNA4 1471/4885ROCK2 3790/4885 |
| US-20090062321-A1 | Hydroxybenzoate Salts Of Metanicotine Compounds | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885ROCK2 3771/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885ROCK2 2944/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | CHRNB2 12/4885CHRNA4 1/4885ROCK2 2664/4885 |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | CHRNB2 8/4885CHRNA4 1/4885ROCK2 3185/4885 |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885ROCK2 2196/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885ROCK2 2944/4885 |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | NTRK1, CHRNA10, CHRNB2 | CHRNB2 3/4885CHRNA4 21/4885ROCK2 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.